Docking and virtual screening of novel inhibitors for mono-ADP-ribosylating toxins
© Scharfe et al; licensee BioMed Central Ltd. 2011
Published: 19 April 2011
Although ADP-RTs are important drug targets, only few inhibitors are known so far. The high selectivity of these inhibitors suggest different mechanism of binding to the ADP-RTs active sites. To explain the structural differences, we started a systematic program towards the development of new ADP-RT inhibitors. This is based on multiple virtual screening experiments (e.g. docking, pharmacophore searching and binding free-energy calculations) and the development of an in vitro assay for ADP-RTs. Active compounds identified in the first screening round are the basis for further in silico studies and optimisation steps. The aim of the current work is the discovery of novel drug-leads and the formulation of structure-function relationships which can explain the selectivity of ligand binding to the NAD+ pocket. This is interesting from a drug discovery perspective, as many enzymes utilizing NAD+ are valid or potential drug targets.
- Krueger KM, Barbieri JT: The family of bacterial ADP-ribosylating exotoxins. Clin Microbiol Rev. 1995, 8: 34-47.Google Scholar
- Holbourn KP, et al: A family of killer toxins. Exploring the mechanism of ADP-ribosylating toxins. FEBS J. 2006, 273: 4579-4593. 10.1111/j.1742-4658.2006.05442.x.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.